Skip to main content
PLOS Pathogens logoLink to PLOS Pathogens
. 2026 Jan 30;22(1):e1013919. doi: 10.1371/journal.ppat.1013919

Prevalence and mechanisms of high-level carbapenem antibiotic tolerance in clinical isolates of Klebsiella pneumoniae

Trevor Cross 1,2,#, Facundo Torres 1,2,#, Nadia Nikulin 1,2,#, Abigail P McGee 2,¤, Leena Jalees 2, Rhea Balakrishnan 2, Tolani Aliyu 2, Lars F Westblade 3, Abhyudai Singh 4, Tobias Dörr 1,2,5,6,*
Editor: Renee M Fleeman7
PMCID: PMC12880740  PMID: 41616033

Abstract

Antibiotic tolerance is the ability of bacteria to survive normally lethal doses of antibiotics for extended time periods. Clinically significant Enterobacterales, for example, can exhibit high tolerance to the last-resort antibiotic meropenem. Meropenem tolerance is associated with formation of cell wall-deficient spheroplasts that readily recover to rod shape and normal growth upon removal of the antibiotic. Both the true prevalence of tolerance, and genetic mechanisms underlying it, remain poorly understood. Here, we find that meropenem tolerance is widespread among clinical Enterobacterales. Using forward genetics, we uncover tolerance factors in a hypertolerant isolate of the ESKAPE pathogen Klebsiella pneumoniae. We find that multiple mechanisms contribute to tolerance, and that cell envelope stress responses (PhoPQ, CpxPRA, Rcs phosphorelay and OmpR/EnvZ) collectively promote spheroplast stability and recovery, while the lytic transglycosylase MltB counteracts it. Our data indicate that tolerance is widespread among clinical isolates, and that outer membrane maintenance is a key factor promoting survival of tolerant K. pneumoniae.

Author summary

Bacteria can survive exposure to antibiotics by constantly repairing cellular damage induced by the drug. This “antibiotic tolerance” enables diverse bacteria to survive long enough to ultimately develop full antibiotic resistance. How they do that, and how widespread this phenomenon is in the clinic, is not well-known. Here we show that tolerance to a last-resort antibiotic, meropenem, is widespread in clinical isolates. Using one bacterium (Klebsiella pneumoniae, which can cause devastating pneumonia and bloodstream infections) as an example, we use a genetic screen to uncover genes that are required for tolerance. Such genes could encode targets for the future development of compounds that help antibiotics kill tolerant bacteria more effectively.

Introduction

Healthcare-associated infections are common sequelae of hospitalization. Increasingly, treatment of these infections fails due to antibiotic resistance [1]. However, treatment also often fails despite the absence of outright resistance [2]. This has been attributed to other bacterial strategies for evading complete eradication, including the well-characterized phenomenon of bacterial persistence [3]. However, between the extremes of frank resistance and persistence, there is considerable complexity in bacterial antibiotic susceptibility patterns. For example, antibiotic tolerance, which has recently received increased attention as another means of surviving antibiotic insult, represents a state where a large fraction of susceptible bacteria survives in the presence of an antibiotic for extended periods, but does not proliferate. Gram-negative bacteria in particular can enter a non-replicative, cell wall-deficient spheroplast form upon treatment with β-lactam antibiotics [47]. This phenotype is reminiscent of L-forms [810] with the distinction that spheroplasts (unlike L-forms) do not proliferate in the presence of antibiotic. Spheroplasts are metabolically active, remain intact for extended time periods and readily recover their cell shape and resume division when the β-lactam drug is removed. Unlike in the case of heterotolerance (persistence) [3], spheroplast survival is afforded not by preventing antibiotic-induced damage through dormancy or reduction in growth rate, but rather by damage management through activation of stress responses [1114]. While tolerant spheroplasts have been characterized in diverse Gram-negative pathogens [57], the true prevalence of β-lactam tolerance among Gram-negative clinical isolates remains unknown.

Klebsiella pneumoniae is a Gram-negative nosocomial pathogen that can cause a variety of opportunistic infections, including eponymous pneumonia, bloodstream infections and UTIs [15]. A member of the infamous ESKAPE group of pathogens, K. pneumoniae exhibits particularly worrisome levels of treatment failure [16]. Due to the high level of resistance against most β-lactams, the carbapenems remain one of the leading antibiotic classes that are still effective against K. pneumoniae [17]. Determining mechanisms that alter susceptibility against β-lactams in general, and carbapenems in particular, is thus a critical need for developing new treatment options against K. pneumoniae. β-lactams covalently and irreversibly bind to so-called penicillin-binding proteins (PBPs), which are the principal synthases of the main cell wall component peptidoglycan (PG). β-lactam binding results in several downstream events that contribute to cell death in poorly-defined ways [13]. Endogenous cell wall lytic enzymes (collectively referred to as autolysins) degrade PG into monomers and ultimately eliminate the sacculus entirely. In some bacteria, cell wall degradation can cause catastrophic rupture and cell lysis, for example in the well-studied model organism E. coli [13]. In addition, the constant synthesis and immediate autolysin-mediated degradation of PG (futile cycling) depletes cellular resources, potentially exacerbating detrimental effects independent of cell lysis [18,19]. Interestingly, β-lactam exposure coincides with the generation of damaging reactive oxygen species (ROS), though the contribution of ROS to β-lactam killing is not entirely clear [11]. It is thought that the combination of these direct and indirect effects collectively contributes to cell death by lysis and/or internal damage. How tolerant cells manage this assault to stay alive has remained poorly understood, but previous work has implicated cell envelope stress signaling in spheroplast survival [11,12,20]. In the cholera pathogen Vibrio cholerae, for example, the VxrAB system is induced by β-lactam stress, resulting in the upregulation of cell wall synthesis functions (which likely readies the cell for recovery once the antibiotic is removed) and downregulation of detrimental iron influx (putatively to reduce the damage sustained by ROS production) [11].

In this study, we sought to characterize meropenem tolerance in K. pneumoniae. We found that clinical isolates of this nosocomial Gram-negative pathogen often exhibit high levels of meropenem tolerance. Using TnSeq, we defined genetic requirements for tolerance, and uncovered a role for cell envelope stress signaling systems in both spheroplast maintenance and recovery. Our data open the door for a more in-depth understanding of the molecular mechanisms promoting tolerance, priming the future design of antibiotic adjuvants that eradicate tolerant cells.

Results

Klebsiella species clinical isolates exhibit high meropenem tolerance

As part of a larger effort to determine the role of antibiotic tolerance in healthcare settings, we characterized a large panel of bloodstream isolates from the culture collection of Weill Cornell Medicine (WCM). This de-identified 271 isolate panel (S1 Table) has been fully characterized through antimicrobial susceptibility testing and consists of Gram-negative pathogens that are mostly carbapenem-susceptible (MIC < 1 µg/mL), with three isolates testing as intermediate (MIC = 2) and seven strains as fully resistant (MIC > 4 µg/mL; one strain due to its possession of a KPC carbapenemase). Specifically, the panel consists of 52% Escherichia coli isolates, 30% Klebsiella pneumoniae, 9% Pseudomonas aeruginosa, 6% Enterobacter cloacae complex, 2% Klebsiella variicola and 1% Acinetobacter baumannii complex. Since the majority of the isolates are carbapenem susceptible, we considered this an ideal panel for determination of how prevalent carbapenem tolerance (rather than resistance) is in clinical samples. Currently, no fully-established sufficiently high throughput tolerance assay exists (we considered another established tolerance test, the TDtest [21] as less effective for our purposes due to the high number of plates required), and we therefore chose to use a semi-quantitative assay for our screen. To this end, we grew the isolate panel (curated to remove the resistant isolates with MIC > 4 µg/mL, with the exception of the KPC producer as an example of full resistance) in a 96-well format, where we exposed cells to meropenem (10 µg/mL, 5x – 100x MIC) at high cell densities (following a 10-fold dilution of overnight culture into fresh medium) in Brain-Heart Infusion broth. At the 8 hour and 24 hour timepoints, 5 µL of thus-treated cultures were then spotted on an agar plate together with 5 ng of purified carbapenemase (KPC-2) to remove the antibiotic. After 24 hours of incubation, spots were then scored as full growth (a confluent spot = high tolerance), growth with a few visible colonies (= intermediate) or no growth (= low tolerance) (Fig 1A and S2 Table). Since this panel contained isolates exhibiting a wide distribution of susceptibilities to meropenem (MICs ranging from ≤0.015 – 4 µg/mL), we considered the possibility that apparent differences in tolerance may instead reflect differences in MIC. Plotting tolerance categories over MIC values revealed that all 3 tolerance categories contained isolates with similar variance in MICs (Fig 1B). As an example, all isolates in Fig 1A with a yellow circle had comparatively high MICs (>/ = 1 µg/mL), but displayed very different survival levels at 8 and 24 hours of meropenem exposure. While we did observe a slight and statistically significant positive correlation between tolerance category and MIC (Spearman coefficient ρ = 0.22, p = 3.72-4) (Fig 1B), the large overlap in MIC between categories and the weakness of the correlation suggest an insignificant relationship between tolerance and intrinsic resistance. Thus, tolerance as determined in this assay is not a simple function of MIC variation; rather, these data suggest that our assay largely captures true tolerance.

Fig 1. Widespread meropenem tolerance among bloodstream isolates.

Fig 1

(A) A panel of susceptible bloodstream isolates (meropenem MIC < / = 4 µg/mL, n = 263, see text for details) was exposed to 10 µg/mL (>2x MIC for all isolates) meropenem in 96-well format (BHI medium) and incubated for 8 hours or 24 hours. Following incubation, purified KPC-2 enzyme was added to the wells, and 10 µL transferred to a BHI plate without antibiotic. Tolerance was scored qualitatively as the ability to form colonies/confluent growth after 8 or 24 hours. Yellow circles indicate examples of different tolerance levels across high MIC (>/ = 1 µg/mL). Red circle indicates a positive control isolate (resistant, KPC+). Red box indicates examples of (from left to right) a highly tolerant Klebsiella pneumoniae isolate, an intermediate tolerant E. coli and a low tolerant E. coli. Shown is a representative panel from 3 biological replicates (B) Tolerance categories were plotted with their corresponding MIC values). Black line indicates weak correlation between tolerance and MIC (Spearman’s coefficient = 0.22); grey area represents 95% confidence interval. Raw data are color-coded according to species (C) Genus distribution among the tolerance categories.

We then asked whether some genera were more likely to exhibit tolerance than others, and to this end plotted tolerance as a function of bacterial genus. Interestingly, the low tolerance fraction was almost exclusively occupied by E. coli isolates (consistent with our previous, qualitative observations [7]), while in the high tolerance fraction, Enterobacter species, Pseudomonas aeruginosa, and especially Klebsiella pneumoniae were highly represented (Fig 1C and S2 Table). Statistical analysis confirmed a strong enrichment for E. coli in the low tolerance category (odds ratio = 59.94, p = 5.2x10-13), and enrichment for K. pneumoniae in the high tolerance category (odds ratio = 7.18, p = 8.4x10-9). Thus, K. pneumoniae clinical isolates in this panel are more likely to display antibiotic tolerance compared to E. coli.

The K. pneumoniae TS1 isolate is highly meropenem tolerant

Since K. pneumoniae clinical isolates answered our survey as particularly tolerant, we chose to focus on this species for further study of meropenem tolerance. However, we noted that different K. pneumoniae isolates diverged in tolerance levels in our spot assay (Fig 1A). To more quantitatively determine strain-specific differences, and to identify new model strains for mechanistic studies, we compared two well-characterized clinical isolates of K. pneumoniae for their tolerance levels in vitro, namely K. pneumoniae strains TS1 (a derivative of the CDC isolate bank AR0080) and KPNIH1 [22]. Both strains have been cured of their carbapenemase-containing plasmids and are thus fully meropenem susceptible with MIC’s of 0.05 (KPNIH1) and 0.0625 - 0.1 (TS1), respectively (S3 Table). Time-dependent killing experiments in the presence of 10 µg/mL meropenem revealed substantial differences in tolerance levels between the two strains, despite their similar susceptibility (Fig 2).

Fig 2. K. pneumoniae TS1 is a hypertolerant clinical isolate.

Fig 2

(A) Example time-dependent killing experiment (BHI medium) in meropenem (10 µg/mL) reveals differences in tolerance levels among two K. pneumoniae isolates (with the model E. coli strain MG1655 as comparison). (B) Tolerance in K. pneumoniae is associated with spheroplast formation. Aliquots from the experiment depicted in panel (A) were transferred to agarose slides at the indicated time-points and imaged. The shown panels are representatives of multiple imaged fields (C) Recovery after addition of purified KPC-2 carbapenemase demonstrates spheroplast viability. Scale bar  =  10 µm.

This observation supports our previous finding of often different tolerance levels between different isolates of the same species [7]. Both K. pneumoniae strains still exhibited higher levels of survival relative to the low-tolerance E. coli MG1655 comparison strain, which exhibited a steep, 4.5 log reduction in viability within six hours of meropenem treatment, and complete elimination by 24 hours of exposure. The TS1 strain was almost completely tolerant, with only a slight (5–10-fold) decrease in viability even after 24 hours of exposure (Fig 2A). In contrast, the KPNIH1 isolate lost viability by 10,000-fold after 24 hours. In both Klebsiella isolates, survival coincided with formation of cell wall-deficient spheroplasts (Fig 2B) that readily recovered to rod shape morphology upon removal of the antibiotic (Fig 2C). We also used these three benchmark strains to validate our semi-quantitativetolerance spot assay (Fig A in S1 Text). Consistent with the time-dependent killing experiments (Fig 2A), TS1 scored as highly tolerant, KPNIH1 as intermediate, and MG1655 as non-tolerant in the spot assay (Fig A in S1 Text). Thus, the TS1 isolate is highly meropenem tolerant, and serves as an ideal model for a mechanistic characterization of spheroplast formation and recovery.

A TnSeq approach reveals putative tolerance genes in K. pneumoniae TS1

We next sought to identify factors that contribute to meropenem tolerance in K. pneumoniae. To this end, we conducted a transposon-insertion sequencing screen to assemble a genome-wide mutant fitness map in the presence of meropenem and compared insertion frequencies before and after 6 hours of meropenem exposure (including an outgrowth step, see methods for details, Fig 3A).

Fig 3. TnSeq identifies genetic determinants of meropenem tolerance.

Fig 3

(A) Outline of TnSeq experimental procedure. Created in Biorender (Doerr, T. 2026. https://app.biorender.com/citation/69494ab2136772694a43eca2) (B) Identification of candidate tolerance factors in TS1 by plotting insertion density of a recovered library vs. the input library. Shown is a scatterplot of Tn insertion frequencies before (x-axis) vs. after (y-axis) meropenem exposure (inset indicates all genes, main panel represents a zoomed version of the red box in the inset). Bona fide tolerance genes are those that have a lower insertion frequency after exposure vs. pre-exposure. Red and green dots represent examples of tolerance genes prioritized for further validation (C) Validation of TnSeq hits. Mutants were obtained from the KPNIH1 mutant library and exposed to meropenem (10 µg/mL) for 6 hours, followed by dilution and spot-plating. Shown is survival fraction (CFU/mL at T6/CFU/mL at T0). Raw data of 3 independent biological replicates are shown + /- standard deviation. Red dotted line indicates WT average survival level. Red bars indicate cell envelope stress response systems; green bars represent genes involved in cell wall homeostasis. Statistical significance was established via Kruskal-Wallace test comparing each mutant to WT.

The screen uncovered both expected and novel putative tolerance genes (Fig 3B and S4 Table). Notably, the gene coding for PBP1b was detected within the top two percent of candidate essential genes for tolerance to meropenem. Class aPBPs like aPBP1b have an established role in rebuilding the cell wall after damage [14,23], and thus serve as internal validation of our screening conditions, establishing confidence in our TnSeq approach. Next, we validated our most prominent hits (i.e., those with the highest insertion rate pre- vs post-exposure). We used an ordered transposon insertion library in the intermediate tolerance strain KPNIH1 for a first-pass validation. We chose the KPNIH1 strain due to easy access to a large number of mutants through this library, which was generated by the Manoil lab [22]. This resulted in confirmation of several genes whose inactivation either promoted or reduced tolerance (Fig 3C). The reduced tolerance fraction contained cell envelope functions, albeit some without statistical significance, due to the high variance in this pilot screening assay (Fig 3C, green bars). An involvement of cell envelope functions is expected due to the need to re-establish a cell wall upon spheroplast recovery. We also noticed that disruptions in several cell envelope stress response systems (rcs, pho, cpx, and ompR-envZ), drastically and statistically significantly reduced survival during meropenem stress (Fig 3C, red bars), while two gene disruptions (in the gene for the cell wall lytic enzyme MltB, and in the poorly characterized outer membrane lipoprotein OsmB), increased survival. Taken together, these results demonstrate that the K. pneumoniae TnSeq experiment was effective at identifying specific genes with roles in meropenem tolerance, lending themselves to further study as outlined below.

The lytic transglycosylase MltB endogenously reduces meropenem tolerance

Our TnSeq screen identified both genes that promote meropenem tolerance as well as genes whose products are actually detrimental in the presence of antibiotic. Inactivation of the gene coding for the lytic transglycosylase (LTG) enzyme MltB, for example, answered the screen as imparting a fitness advantage in the presence of meropenem, suggesting that MltB plays a role in meropenem-mediated killing. The specific phenotype for MltB was unexpected, since bacteria generally have many functionally redundant lytic transglycosylase paralogs throughout their genomes, and phenotypes associated with a single deletion are thus rare [24]. To dissect the role of LTGs in meropenem tolerance further, we tested a panel of transposon disruption mutants in known and predicted LTG genes for meropenem tolerance in the lower tolerance strain KPNIH1. Among eleven mutants tested, only mltB::tn and (to a lesser degree) sltY::tn exhibited significantly increased survival in the presence of meropenem, with a drastic 1000-fold increase in survival (compared to WT) after 24 hours for mltB and 100-fold for sltY (Fig 4A). Time-dependent killing experiments confirmed a strong role for MltB as an antagonist of antibiotic tolerance, as the mltB::tn mutant exhibited minimal (5-fold) killing in the presence of meropenem over 24 hours (Fig 4B); this phenotype could be complemented by expressing inducible mltB from a neutral chromosomal locus (Fig B in S1 Text).

Fig 4. MltB and SltY reduce tolerance to meropenem and prevent cells from retaining polar morphology.

Fig 4

(A) Survival of mutants in lytic transglycosylases. Mutants were obtained from the KPNIH1 mutant library and exposed to meropenem (10 µg/mL) for 6 hours, followed by dilution and spot-plating. (B) Time-dependent killing reveals increased tolerance in an mltB mutant. Shown are mean + /- SD of 6 biological replicates for mltB::tn (3 replicates for both WT) * = p < 0.05, Mann Whitney test. (C) Cell wall degradation in LTG mutants. Bacteria were treated as described for A) and then imaged at the indicated timepoints. Red arrow points to an example of a retained pole in mltB::tn. The hypertolerant TS1 strain is shown as comparison. Example images from 2 independent experiments with similar results are shown. Scale bars, 10 µm.

The mltB::tn and sltY:tn mutants were further characterized by examining cell morphology upon spheroplast formation. Timelapse microscopy of cells exposed to meropenem revealed that the mltB::tn and sltY:tn disruption mutants were clearly damaged by the antibiotic (forming spheroplasts). However, mltB::tn retained morphology at the cell poles for longer than the parent strain (Fig 4C, red arrow), and qualitatively exhibited an increase in the relative abundance of intact spheroplasts (Fig 4C). These data suggest that mltB and (to a lesser extent) sltY may reduce tolerance by accelerating the degradation of peptidoglycan when synthesis is halted by meropenem, and thus point to a dominant role of these LTGs in cell wall turnover in K. pneumoniae. Perhaps activation of autolysins could be a useful future strategy to potentiate β-lactam antibiotics against tolerant pathogens.

Multiple cell envelope stress response systems collectively contribute to β-lactam tolerance

Several well-characterized cell envelope stress response systems (CESRs) appeared in our screen as top candidates that promote meropenem tolerance: the Rcs phosphorelay system, the PhoPQ and CpxAR two-component systems, and the osmotic and acid stress response TCS, OmpR/EnvZ. Of note, our previous work revealed the PhoPQ system as a key meropenem tolerance determinant in the fellow Enterobacterales, Enterobacter cloacae, suggesting that PhoPQ-mediated tolerance may be a widely conserved [25]. To dissect the individual and combined contributions of these systems to survival in meropenem, we created deletions of all four systems in all combinations, including one quadruple system deletion mutant lacking all four stress responses, in our hypertolerant TS1 strain. These mutants were then exposed to meropenem in time-dependent killing assays. These experiments revealed a 10–10,000-fold decrease in viability after 24 hours of exposure to meropenem in any individual envelope stress response mutant compared to the wild type K. pneumoniae parent strain (Fig 5A and 5B), which could be complemented by expressing each respective system from a neutral chromosomal locus (Fig C in S1 Text). We observed large differences in both magnitude and consequences for lysis in the different mutants. The ΔompR/envZ mutant, for example, exhibited the most drastic reduction in viability of all the single mutants (10,000-fold vs. 10- to 100-fold for the others), pointing to a particularly important role of the OmpR/EnvZ response in tolerance to meropenem. We also noticed that while most single mutants exhibited both a drop in CFU/mL and in OD600 (indicative of cell lysis), the ΔrcsF mutant was only defective in viability, with only a slight reduction in OD during meropenem treatment (Fig 5A), suggesting a role for RcsF in spheroplast recovery, rather than structural maintenance.

Fig 5. Cell envelope stress response systems are essential for full meropenem tolerance.

Fig 5

TS1 and its CESR mutant derivatives were diluted 10-fold into 5 mL of BHI medium containing 10 µg/mL meropenem. At the indicated timepoints, samples were withdrawn and OD600 (A) and CFU/mL (B) were measured. Data represent means + /- standard deviation of at least 4 biological replicates. At 24 hours, differences between each mutant and WT, and between ∆4 and each single mutant except ∆ompR/envZ were statistically significant (Mann Whitney U test, p = 0.002). (C) Aliquots were removed from the experiment depicted in (A-B) and imaged. Scale bar = 10 µm.

We also investigated cell morphologies of each mutant before and after exposure to meropenem for 24 hours of treatment, and upon recovery in strains capable of forming spheroplasts. Wild type cells and all single deletion mutants appeared similar in shape and morphology at the start of meropenem exposure experiments (Fig 5C). However, the Δ4 cells exhibited slightly aberrant morphology (slightly larger cells with subtle deformations) and spontaneous lysis, suggested by the presence of cell debris. After 24 hours of meropenem exposure, the WT formed robust spheroplasts, as previously observed. In contrast, spheroplast numbers were dramatically reduced in the ΔompR/envZ,cpx and ∆phoPQ mutants (virtually absent from the ompR/envZ mutant). The rcsF mutant formed robust spheroplasts, consistent with the relatively minor reduction in OD600 post-treatment (Fig 5C). Thus, the Rcs system may play a role in spheroplast recovery, rather than cell envelope maintenance, consistent with a role in spheroplast recovery in lysozyme-treated E. coli [26]. Interestingly, the ΔompR/envZ and Δ4 mutants were highly defective in spheroplast formation or maintenance, as we failed to find any intact spheroplasts even upon 10-fold concentration of meropenem-treated culture followed by imaging, consistent with the drastic reduction in viability these strains experience in the presence of meropenem (Fig 5B). We also constructed intermediate strains, including a suite of ∆3s with single two-component systems left intact (Fig D in S1 Text). All ∆3s collapsed in viability almost to the same degree as the ∆4, strongly suggesting an additive or synergistic effect between the different systems, as no two-component system by itself could sustain viability. Of note, among the ∆2 mutants, the combination of ∆ompR/envZ and ∆rcsF was most detrimental, and the resulting mutant was, like the ∆4 mutant, nearly eradicated after 24 hours of exposure. Collectively, these results point to a functionally hierarchical organization of responses necessary for meropenem tolerance: OmpR/EnvZ as the most important response, followed by Pho and Cpx to maintain spheroplast stability, and Rcs with a more prominent role in recovery compared to maintenance of structural integrity.

The Rcs phosphorelay is induced by, and required for, meropenem tolerance

The Rcs phosphorelay as an apparent contributor to tolerance caught our attention. In E. coli, Rcs is induced by β-lactams, and required for survival in low β-lactam concentrations [27]. Additionally, Rcs is required for recovery of E. coli from a cell wall-deficient state (generated by lysozyme treatment in osmostabilized medium, a condition that morphologically mimics meropenem-treated spheroplasts) [26]. In apparent contrast, a recent study has shown that Rcs is neither induced by, nor required for β-lactam persisters [28]; however, this is likely because persisters are dormant and thus not expected to be damaged by the antibiotic (obviating the need for a damage response) [3]. To clarify the role of Rcs in K. pneumoniae, we engineered a TS1 strain carrying an PrprA-lacZ transcriptional fusion (a well-established readout of Rcs signaling [29]) in a neutral chromosomal locus (lacZ) and measured induction by meropenem. A first qualitative assay using zone of inhibition on growth medium containing the chromogenic LacZ substrate X-gal yielded a blue ring around the zone of inhibition when a meropenem disk was placed on the agar surface, but not when the translation inhibitor kanamycin was used (Fig E in S1 Text). We then corroborated these results in liquid medium, where a quantitative β-galactosidase activity assay (Miller assay) revealed a 5-fold induction of the construct by meropenem that was largely dependent on the presence of RcsB (Fig 6A). Thus, meropenem induces the Rcs response. We also validated the role of Rcs in meropenem tolerance by creating additional mutants in Rcs components, namely RcsC and RcsD. All mutants displayed a strong (10,000-fold) reduction in tolerance, which could be fully complemented by overexpression of the response regulator RcsB (Fig 6B). The ability of RcsB overexpression to induce the Rcs regulon was verified by measuring induction of the chromosomal PrprA-lacZ construct (Fig E in S1 Text). Thus, the Rcs phosphorelay is both responsive to meropenem exposure, and required for meropenem tolerance in K. pneumoniae.

Fig 6. The Rcs phosphorelay is induced by meropenem and required for tolerance.

Fig 6

(A) WT and ∆rcsBCD strains carrying a chromosomal rprA-lacZ transcriptional fusion were exposed to meropenem, followed by quantification of β-galactosidase activity via Miller assay. A strain deleted in lacZ was used as background control. ** = p < 0.05, ns = not significant (t-test) (B) The indicated strains were exposed to meropenem (10 µg/mL). Survival fraction is CFU/mL after 24 hours normalized to starting cell density. Shown are averages of 3 independent experiments + /- standard error. Statistical significance was tested via Welsh’s t-test on log-transformed data (** = p < 0.05). Each single mutant was also statistically significant from WT (p < 0.05, Welsh’s t-test on log-transformed data, omitted from graph for clarity).

Fluctuation test reveals memory in tolerant subpopulation

The stress responses that contribute to meropenem tolerance may rely on deterministic induction by the antibiotic for their protective impact, or they may be stochastically and heterogeneously active within the population before exposure to a stress as a bet-hedging strategy. To gain some insight into this distinction, we leveraged the classical Luria-Delbrück experiment or the “Fluctuation Test” that has been recently expanded to investigate reversible switching between cellular states within an isogenic cell population. This fluctuation test has been used to gain insights into the non-genetic mechanisms by which microbial and cancer cells survive lethal exposure to targeted drug therapy [3032]. For example, the application of the fluctuation test in Escherichia coli [33], Bacillus megaterium [34] and Mycobacterium tuberculosis [35] has shown individual cells to reversibly switch between an antibiotic-sensitive and an antibiotic-tolerant state, with each state being maintained transiently for several generations. This reversible switching happens continuously in the absence of the drug as a result of stochastic fluctuations in underlying signaling and gene regulatory networks and primes a rare subpopulation of cells as a bet-hedging mechanism to survive lethal antibiotic exposure.

To conduct a fluctuation test, we first isolated single TS1 cells in 96-well plates using serial dilution. Each cell was grown into a clonal population and exposed to meropenem at an OD600 of 0.3 (Fig 7). WT OD dropped sharply at first, followed by slower increase in OD600 in the surviving subpopulation (spheroplasts). The clone-to-clone fluctuations in cell viability after antibiotic exposure were quantified by using the coefficient of variation (standard deviation divided by the mean) of OD600 (spheroplast survivor fraction) across clones at 1.66 hours after drug exposure. This time point was specifically chosen as it captures the OD600 drop-off in response to meropenem (Fig 7, dashed vertical blue line) and avoids the rebound in OD600 seen in WT cells as a result of changes in cell shape. We then used mathematical modeling to predict how the kinetics of switching between drug-sensitive and drug-tolerant cell states impact clone-to-clone fluctuations in the number of cells surviving lethal stress, with slower switching (i.e., higher transient memory of a state being retained across generation) resulting in a higher degree of interclonal fluctuations [32]. Our results show clone-to-clone fluctuations in cell integrity to be 0.153 ± 0.036 for WT where ± denotes the 95% confidence intervals in the coefficient of variation of OD600 as obtained by bootstrapping (Fig 7). These observed fluctuations were significantly higher than the technical noise of 0.086 ± 0.028 (control fluctuations). Technical noise was estimated by performing a similar experiment, but with fluctuations quantified across wells starting with a random population of 10,000 cells rather than a single cell-derived population. These results were statistically significant (testing for equality of CVs [36]; p = 0.0031 for WT 1 cell vs. 104 cells). Similar to observations in other bacteria, this fluctuation data is consistent with a model of a multi-generation drug-tolerant state in Klebsiella pneumoniae that preexists meropenem exposure.

Fig 7. Fluctuation test indicates memory in spheroplast population.

Fig 7

Bacteria were diluted to a starting density of 1 cell/well or 10,000 cells/well (control), and grown in a microtiter plate. At OD600 = 0.3, meropenem (10 µg/mL) was added (red dotted line). CV (coefficient of variation) calculations were performed at peak killing (blue dotted line).

We hypothesized that the stochasticity originated from variance in background expression of cell envelope stress responses. To test this, we repeated the fluctuation assay in the Δ4 genotype where the observed fluctuations were much smaller compared to WT with the coefficient of variation being 0.044 ± 0.009 (p = 9.7 x 10-6 one cell vs. 104 cells), but still significant compared to control fluctuations performed for this strain (Fig 7). The lower value of the observed clonal fluctuations in Δ4 points to faster-switching kinetics, and hence a shorter transient memory of the drug-tolerant state, suggesting that at least part of the heterogeneity in tolerance levels is caused by stochastic baseline expression levels of cell envelope stress response systems.

Discussion

Infections with Enterobacterales continue to be an active and increasing threat to public health due to their capacity to cause infection, and to gain and disseminate antibiotic resistance genes, with particular risk for vulnerable populations. In this work, we have found that antibiotic tolerance, the ability to sustain viability in the presence of bactericidal antibiotics for extended time periods, is widespread among clinical isolates of Gram-negative pathogens, particularly Klebsiella pneumoniae.

To uncover novel factors that modulate β-lactam tolerance in K. pneumoniae we performed a genome-wide scan using a TnSeq approach. Because this approach provides a readout of each gene’s fitness during a challenge, we were able to identify genes that contribute to meropenem tolerance, and genes that reduce tolerance in K. pneumoniae. The screen overall was able to capture several regulatory systems and individual factors that modulate tolerance along with the internal control PBP1b (a key cell wall synthase required to rebuild the cell wall after catastrophic damage [23]), raising confidence in our approach. This screen also pointed to several cell envelope stress responses that are partly responsible for this strain’s ability to undergo the entire process of spheroplast formation, maintenance, and recovery: the Rcs, Pho, Cpx, and OmpR/EnvZ systems. Of note, the ability of cell envelope stress responses to confer antibiotic tolerance via repair of antibiotic-induced damage appears to be widespread among diverse bacteria [11,13,37,38].

Interestingly, the OmpR/EnvZ system appears to exert a particularly strong effect on tolerance. This system is induced by changes in pH and osmolarity, and in E. coli controls the switch from the larger diameter porin OmpF to the smaller diameter porin OmpC [39]. Formally, it is possible that the porin switch may delay diffusion of meropenem into the cell; however, this is unlikely to account for the tolerance phenotype we observe here, given that WT and ∆ompR/envZ MICs are within essential agreement (S2 Table). Future work will be directed at delineating the contribution of this system to spheroplast maintenance. Conversely, the Pho and Cpx single system deletion mutants appear to have similar net contributions to meropenem tolerance both in rate of killing and final viability, while still forming detectable spheroplasts capable of recovery. The versatile PhoPQ system senses Mg2+ deficiency, presence of antimicrobial peptides, pH and other stresses [40]. Most relevant to the phenotype assayed here, we have previously shown that PhoPQ is required for meropenem tolerance in the related bacterium Enterobacter cloacae, via PhoPQ-controlled outer membrane modifications [25]. The Cpx system is a general cell envelope health monitor [41], which controls, among other things, L,D-transpeptidases that help stabilize the outer membrane [42,43], and respiratory chain functions [44,45], which contribute to ROS production in spheroplasts [11]. Lastly, the Rcs system contributes to meropenem tolerance in a unique way. Time-dependent killing revealed that viability dropped substantially in the ΔrcsF mutant, but this strain’s capacity to form spheroplasts and maintain optical density was comparable to the WT parent strain. However, ΔrcsF mutant spheroplasts were markedly impaired in their ability to reform successful dividing rods when meropenem is removed. Among other genes, Rcs positively regulates the cell division component ftsZ [46], perhaps pointing to a model where upon spheroplast recovery, cell division can commence sooner in WT than in ∆rcs cells due to the increased availability of critical divisome components. Taken together, the phenotypes of each individual mutant indicate that aspects of β-lactam tolerance are mediated by distinct response systems, likely with some temporal distinction (Fig 8). These responses (or at least the general strategy of cell envelope damage repair via stress response systems) appear to be a well-conserved mechanism of β-lactam tolerance, as stress response systems (including some of the systems revealed here) have been identified as contributors to survival in the presence of β-lactams in E. coli [47], Acinetobacter baumanii [48], and Burkholderia pseudomallei [20].

Fig 8. Summary of meropenem tolerance as a net result of cell wall degradation and cell envelope stress response induction.

Fig 8

Meropenem treatment induces multiple cell envelope stress responses, whose regulons contribute to survival. Lytic transglycosylases MltB and SltY contribute significantly to sacculus degradation, which reduces efficiency of spheroplast recovery. Partially created in Biorender (Doerr, T. 2026. https://app.biorender.com/citation/6945955a37d46757be2b127c).

Because TnSeq has the benefit of also revealing gene disruptions that increase fitness, we simultaneously probed for endogenous factors that reduce meropenem tolerance. K. pneumoniae strain TS1’s lytic transglycosylase mltB answered the screen as a strong candidate that actually improves survival when disrupted, which conversely suggests that MltB contributes to cell killing in the presence of meropenem. Lytic transglycosylases cleave glycosidic bonds of peptidoglycan strands [24], and have specific and important functions in opportunistic pathogens. For example, in Acinetobacter baumannii, mltB is a critical factor for pathogenesis by linking complex envelope homeostasis functions with virulence [49]. In Pseudomonas aeruginosa, eliminating this enzyme (also in combination with other lytic transglycosylases) increases resistance to cell-wall targeting antibiotics via induction of an endogenous β-lactamase [50,51]. Disruption of sltY and mltB in K. pneumoniae strain KPNIH1 resulted in 10- to 1000-fold increased tolerance to meropenem. Cell morphology around the poles in these mutants was maintained after exposure to meropenem, possibly due to this strain’s inability to degrade the old peptidoglycan present when PBPs are inhibited. This maintenance of the cell wall could be what increases survival by preserving the peptidoglycan and envelope-spanning systems, leading to preservation of cell integrity and potentially serving as a scaffold for new cell wall synthesis when meropenem is removed. It is unclear why mltB and sltY specifically emerge as the only lytic transglycosylases that have this effect on the cell when bacteria generally have multiple redundant lytic transglycosylase paralogs in their genomes; strong phenotypes for single deletion mutants are thus highly unusual. In E. coli, deletion of especially slt70 has a somewhat paradoxical effect, where the mutation confers hypersensitivity to the antibiotic mecillinam (i.e., the opposite phenotype to the one observed here), but confers resistance when paired with activation of the divisome through induction of ftsZ. The interpretation in this case is that since mecillinam targets the Rod system for cell elongation, resistance requires a combination of reducing futile cycling (by deleting slt70) and promoting division in the presence of antibiotic (by activation of the FtsZ ring) so that morphologically aberrant cells can still divide [18]. It is possible that the tolerance increase we observe in the mltB/sltY mutants likewise reflects reduced futile cycling, though importantly, spheroplasts do not divide in the presence of antibiotic. We noted that both LTG mutations also increased meropenem MIC significantly (S2 Table). It is thus possible that increased degradation of meropenem, for example by overproduction of a chromosomal β-lactamase with low-level carbapenemase activity, also at least partially contributes to enhanced survival of these mutants (as a caveat, K. pneumoniae’s chromosomal enzyme SHV-1 is not known to hydrolyze carbapenems). However, these mutants still form spheroplasts, indicating significant cell wall damage, ergo meropenem is still present at supra-MIC concentrations. Putative carbapenemase activity can thus not account entirely for the high survival phenotype.

Overall, this study presents a deeper insight into β-lactam tolerance and can inform further investigations to understand other aspects of how these dangerous pathogens respond to antibiotics and ultimately develop resistance. Attaining an understanding of the detailed workings of this complex phenotype can inform approaches toward finding potential druggable targets to reduce or abolish an organism’s capacity for β-lactam tolerance, thus allowing development of novel therapeutics and treatment strategies for tolerant pathogens.

Methods

Culture conditions and killing experiments Unless otherwise stated, all strains were grown in shaking overnight cultures at 37⁰C, and tolerance assays were carried out in Brain Heart Infusion (BHI) broth at 37⁰C. Tolerance assays were conducted by inoculating overnight culture at a 1:10 ratio into fresh BHI medium containing 10 µg/mL meropenem (TCI, Tokyo, Japan). Cultures were then incubated at 37˚C without shaking. Optical density was measured in a VWR V-1200 spectrophotometer and viable cells were quantified by serial dilution in BHI medium and spot-titered onto BHI agar. The carbapenemase KPC-2 was purified (see next section for detail) and added to culture samples at a final concentration of approximately 1 μg/mL prior to serial dilution to deactivate meropenem, thus eliminating meropenem carryover effect. For complementation experiments, 40 ng/mL anhydrotetracycline was added for induction of expression.

MIC Determination

MICs for all strain backgrounds (except the isolate panel, see below) were determined by diluting overnight cultures 107-fold in BHI medium for direct comparison with killing experiments. Diluted cultures were inoculated into BHI containing successive 2-fold concentrations of meropenem in a 96 well microtiter plate at a final volume of 200 µL per well, and incubated at 37°C overnight, leaving one well as an uninoculated control, and one well with cells but without meropenem to ensure growth of the strain. MICs were recorded as the lowest meropenem concentration free from turbidity. For the clinical isolate panel, MICs were measured using standard CLSI guidelines (cation-adjusted MHB).

Purification of KPC-2 enzyme

The gene for KPC-2 was amplified from the genome of Enterobacter cloacae strain 41952, a clinical isolate from WCM, and cloned into the pET21 expression vector. The His-tagged KPC-2 enzyme was overexpressed in BL21 pLysS. A 500 ml culture of LB containing 100 μg/mL ampicillin was induced at OD = 0.5 with 1 mM IPTG and incubated shaking at 30°C overnight. The following day, cultures were centrifuged, and pellets were decanted and stored at -80°C until lysis and purification. Pellets were resuspended in resuspension buffer (20 mM Tris, 150 mM NaCl, 5 mM imidazole) and sonicated using the QSonica with the largest tip attachment for 40 minutes total, alternating between 5 second pulses and 5 second rests on ice. The lysate was then centrifuged for 45 minutes at 16,000 rpm and the supernatant discarded. In preliminary expression experiments, we found that KPC was mostly in the insoluble fraction. The insoluble pellet was resuspended in binding buffer (20 mM Tris, 150 mM NaCl, 5 mM imidazole, 3 M Urea), and incubated rotating overnight at 4°C to denature and solubilize the KPC-2 protein. The next day, the denatured lysate was centrifuged again at 16,000 rpm for 45 minutes, and the resulting supernatant passed through a cobalt-charged NTA agarose resin column at room temperature. Six column volumes of wash buffer (20 mM Tris, 150 mM NaCl, 30 mM imidazole, 3 M Urea) were then passed through the column, and the protein eluted in 1.8 mL fractions with increasing concentrations of imidazole in elution buffers (20 mM Tris, 150 mM NaCl, 50–600 mM imidazole, 3 M Urea). Fractions with the highest protein concentrations were pooled, and the total volume was dialyzed into a final storage buffer (20 mM Tris, 150 mM NaCl, 30% glycerol) in three steps, each with decreasing concentrations of imidazole and increasing concentrations of glycerol. Purity was determined by SDS-PAGE, and concentration was estimated with Bio-Rad Bradford Assay kit.

Imaging

All images were taken on a Leica Mdi8 microscope (Leica Microsystems, GmbH, Wetzlar, Germany) with a PECON TempController 2000–1 (Erbach, Germany), heated stage at 37˚C for growth experiments, or room temperature for static images. For timelapse microscopy of spheroplast formation, cells were placed on a 0.8% agarose pad containing BHI and 10 μg/mL meropenem within a gene frame (ThermoFisher, Waltham, MA). For recovery timelapses, KPC-2 enzyme was added at 5 μg/mL to eliminate the meropenem. Frames were taken using autofocus control every five minutes for up to 12 hours. Timelapse video stacks were processed in FIJI (NIH) using the Linear Stack Alignment with SIFT under the Registration plugin (using all default settings with the exception of Expected Transformation, which was changed to Translation) to center cells in the cropped frame.

Transposon mutagenesis screen and data analysis

K. pneumoniae strain TS1 was mutagenized with a Mariner transposon delivered via the E. coli donor strain MFD λpir to generate a complex library of kanamycin-resistant transposon mutants. This initial library was frozen as a glycerol stock, and an overnight culture from it was grown in BHI containing kanamycin at 50 μg/mL to form an input library as the comparison for TnSeq analysis. Overnight cultures of this input library were diluted 10-fold into 5 mL BHI containing meropenem (10 ug/mL) and incubated for six hours at 37˚C without shaking, followed by plating on BHI agar plates after treatment with 5 μg/mLKPC-2 enzyme (untreated controls were also generated mirroring the six-hour exposure and recovery populations). Genomic DNA (gDNA) was extracted from all stages of the meropenem challenge and recovery and prepared for Illumina sequencing. Briefly, gDNA extracted from each library was sonicated to generate fragments mostly 200–800 base pairs long which were blunted using NEB Quick Blunting Mix (#E1201L). After blunting, fragments were given A-tails with Taq DNA polymerase to allow ligation of adapter sequences. Ligated fragments were amplified with PCR to enrich transposon-adjacent regions, and then again were PCR amplified with primers to add barcodes, spacer sequences, and Illumina chip attachment ends. The library was run on agarose gel and all fragments 250–600 base pairs were extracted for analysis on the BioAnalyzer (Agilent, Santa Clara, CA) to assess before Illumina sequencing. All libraries were sequenced as paired 150 bp reads, though only forward reads were used in the final analysis.

Raw Illumina data were processed in Galaxy using the Cutadapt program to trim reads for length and quality, then mapped with Bowtie2 using the K. pneumoniae TS1 FASTA reference genome available in NCBI (Biosample accession number SAMN04014921). Mapped reads were analyzed by TnSeq Explorer [52] to calculate insertion density of each gene from each library. Insertion densities were used to calculate an insertion density ratio for each gene from one library to another, thereby comparing essentiality across points in the meropenem challenge. The comparison between library 2 (input) and library 6 (meropenem recovery) was used as the basis for ranking genes in order of essentiality, with genes most essential to meropenem tolerance appearing at the top of the list, while genes which impart a fitness increase when disrupted appearing at the bottom of the list.

KPNIH1 validations

Candidate tolerance genes identified by TnSeq were first validated using an arrayed K. pneumoniae KPNIH1 library constructed by the Manoil lab [22]. Transposon mutants were grown in 200 µL BHI medium overnight cultures in a 96 well plate. The next day, the overnight culture was diluted 1:10 into BHI containing a final concentration of 10 μg/mL meropenem. At the indicated time points, samples were taken for CFU determination, while simultaneously measuring optical densities in a Spectramax iX3 (Molecular Devices, San Jose, CA) plate reader, and then incubated at 37˚C without shaking for six hours. Final optical density and CFU/mL were recorded and the ratio between final and initial values were calculated to determine the effect of the gene disruption when challenged with meropenem.

Strain constructions with pTOX

Strains and oligos are summarized in S5 and S6 Tables. Knock out and reporter strains in K. pneumoniae TS1 were constructed using the pTOX5 allelic exchange vector as described in [53]. Briefly, 800–1000 base pair regions flanking regions were amplified using PCR or synthesized de novo and assembled via isothermal assembly into the pTOX SmaI site. Assembled constructs were transformed into DH5α λpir competent cells, plated on LB containing 100 μg/mL chloramphenicol and 1% glucose (LB/CHL/gluc) (to repress the rhamnose inducible toxin gene) and screened for insertion size with primers TC_82 and TC_83, followed by sequence verification through Sanger sequencing. Correct constructs were transformed into conjugal MFD λpir and mated into K. pneumoniae TS1 on LB containing 1% glucose and 1.2 mM DAP (LB/gluc/DAP) for 6 hours at 37°C. Transconjugants were isolated back on LB/CHL/gluc and a single colony was grown out in LB containing 1% glucose until the OD reached 0.1-0.2, at which point cells were washed with M9 medium containing 0.2% casamino acids and 1% rhamnose, and plated on solid M9/rham/casamino acids to induce the counterselective toxin and isolate allelic exchange constructs containing the desired modifications. Envelope stress response system deletions were screened using primers flanking the loci of interest and validated using internal primers. Other constructs were validated using primers specific to the modification, or primers flanking the lacZ locus where reporters were inserted.

For complementation of phenotypes, genes were cloned into a pTn7 plasmid (tn7-gentamycin) and inserted into the chromosomal Tn7 insertion site (near the glmS gene) using triparental mating with the helper plasmid pTNS2. The Tn7 plasmid was modified to contain an anydrotetracycline-inducible (Tet on) gene fragment (DL-GB-PP-1, see S6 Table). MltB and CESRs were amplified from the chromosome of Kp KPNIH1 (mltB) and TS1 (CESR loci), respectively, using primers NN520/521 (mltB), NN518/519 (cpxPRA), NN512/513 (ompR/envZ), NN514/515 (phoPQ), NN516/517 (rcsDBC) and cloned into PacI-digested pTN7 using isothermal assembly. Successful clones were screened for using primers NN522/NN523, and verified via whole plasmid sequencing.

Miller assay to detect RcsB function and induction

To assess function of the RcsB response regulator, a reporter construct was constructed by inserting an rprA-lacZMG1655 reporter with the E. coli MG1655 lacZ gene (abbreviated to rprA-lacZ) into the TS1 native lacZ locus, eliminating most of the native lacI and lacZ genes. This construct was validated first by overexpressing native RcsB on a pBAD plasmid in the presence of 0.2% arabinose on BHI medium from strain TS1 in the reporter background and qualitatively comparing X-gal signal to the construct containing an empty vector. RcsB activation upon meropenem exposure was measured by performing the Miller assay on cell pellets from meropenem-exposed cells at 0, 1, 3, and 6 hours in BHI and control cultures to determine relative units of β-galactosidase activity normalized to CFU/mL of either culture.

Fluctuation test

Fluctuation test experiments in strain TS1 and its Δ4 derivative were done by transferring 100 µL of seed stock (overnight cultures 109-fold in 15 mL BHI medium) into a 96-well plate. At this dilution, every three to four wells receives a single cell. This plate was then incubated without shaking at 37°C in a Spectramax i3x set to read optical density every five minutes. Individual wells that started with the presence of cells were grown to an optical density of 0.3, at which point they were treated with meropenem at a final concentration of 10 μg/mL, and allowed to continue incubating. Datasets were aligned such that all additions of meropenem were at a uniform OD 0.3. Control experiments were set up by inoculating each well with 10,000 colony forming units and growing to optical density 0.3, at which point all individual populations in each well were treated with 10 μg/mL meropenem as above. Co-efficient of variation (CV) in OD values was then calculated upon reaching a plateau of lysis. A higher CV at lower starting density (single cell, more generations before drug exposure) than higher starting density (10,000 cells, fewer generations before drug exposure) indicates transient memory, as increased variation in the population after extended growth indicates that variability is pre-existing, rather than induced by the antibiotic, and multigenerational.

Supporting information

S1 Text

Fig A. Tolerance screen validation with benchmark isolates. Strains were exposed to meropenem (10 µg/mL) as described in methods. At the indicated time-points, 10 µL of the cell suspension was spotted on BHI agar and supplemented with KPC, followed by 24 hours of incubation at 37 ˚C. Fig B. Complementation of the ∆mltB phenotype. The indicated strains were grown overnight in BHI, then diluted 10-fold into fresh BHI containing meropenem (10 µg/mL) and 40 ng/mL anhydrotetracycline. Viability was determined by serial dilution and spot-plating after 24 hours of incubation. Shown are raw data points for 5 biological replicates for each strain. Statistical significance was determined by Mann Whitney test (*p < 0.05). Fig C. Tolerance phenotypes of CESR mutants. Time-dependent killing experiments (10 µg/mL meropenem) were conducted in BHI medium. Statistical analysis (Kruskal-Wallace test, p < 0.001) revealed statistically significant differences in viability (12 hour time point) for all mutants vs. WT; ∆4 vs. any triple mutant was not statistically significant. Fig D. Complementation of the ∆CESR phenotypes. The indicated strains were grown overnight in BHI, then diluted 10-fold into fresh BHI containing meropenem (10 µg/mL) and 40 ng/mL anhydrotetracycline and incubated for 24 hours. Viability was determined by serial dilution and spot-plating. Shown are boxplot and raw data points for at least 5 biological replicates for each strain. Fig E. Meropenem induces the Rcs phosphorelay. A) The PrprA-lacZ reporter strain was spread on plates containing the chromogenic LacZ substrate x-gal. A filter disk was placed in the middle containing either meropenem or kanamycin. Note blue halo around the meropenem disk, in the sub-MIC area beyond the zone of inhibition. B) RcsB was overexpressed from an arabinose-inducible promoter in the PrprA-lacZ background, followed by plating on LB with X-gal.

(DOCX)

ppat.1013919.s001.docx (944.3KB, docx)
S1 Table. Summary of Bloodstream Isolate Panel Distribution in tolerance categories.

Shown are the number of isolates for each species in each tolerance category.

(XLSX)

ppat.1013919.s002.xlsx (32KB, xlsx)
S2 Table. MICs of the strains used in this study.

(XLSX)

ppat.1013919.s003.xlsx (9.2KB, xlsx)
S3 Table. Bloodstream isolate panel.

(XLSX)

ppat.1013919.s004.xlsx (9.5KB, xlsx)
S4 Table. TnSeq insertion frequencies.

(XLSX)

ppat.1013919.s005.xlsx (1.3MB, xlsx)
S5 Table. Strains used in this study.

(XLSX)

ppat.1013919.s006.xlsx (14KB, xlsx)
S6 Table. Oligos used in this study.

(XLSX)

ppat.1013919.s007.xlsx (14.1KB, xlsx)

Data Availability

All relevant data are in the manuscript and its Supporting information files.

Funding Statement

This work was supported by NIH grants R01AI143704 and R01GM130971 to TD. AS acknowledges support from NIH-NIGMS via grant R35GM148351. The funders had no role in study design, data collection and analysis,decision to publish, or preparation of the manuscript.

References

  • 1.Miller WR, Arias CA. ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics. Nat Rev Microbiol. 2024;22(10):598–616. doi: 10.1038/s41579-024-01054-w [DOI] [PubMed] [Google Scholar]
  • 2.Haney EF, Hancock REW. Addressing antibiotic failure—beyond genetically encoded antimicrobial resistance. Front Drug Discov. 2022;2. doi: 10.3389/fddsv.2022.892975 [DOI] [Google Scholar]
  • 3.Balaban NQ, Helaine S, Lewis K, Ackermann M, Aldridge B, Andersson DI, et al. Definitions and guidelines for research on antibiotic persistence. Nat Rev Microbiol. 2019;17(7):441–8. doi: 10.1038/s41579-019-0196-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Roberts D, Higgs E, Rutman A, Cole P. Isolation of spheroplastic forms of Haemophilus influenzae from sputum in conventionally treated chronic bronchial sepsis using selective medium supplemented with N-acetyl-D-glucosamine: possible reservoir for re-emergence of infection. Br Med J (Clin Res Ed). 1984;289(6456):1409–12. doi: 10.1136/bmj.289.6456.1409 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Monahan LG, Turnbull L, Osvath SR, Birch D, Charles IG, Whitchurch CB. Rapid conversion of Pseudomonas aeruginosa to a spherical cell morphotype facilitates tolerance to carbapenems and penicillins but increases susceptibility to antimicrobial peptides. Antimicrob Agents Chemother. 2014;58(4):1956–62. doi: 10.1128/AAC.01901-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Dörr T, Davis BM, Waldor MK. Endopeptidase-mediated beta lactam tolerance. PLoS Pathog. 2015;11(4):e1004850. doi: 10.1371/journal.ppat.1004850 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Cross T, Ransegnola B, Shin J-H, Weaver A, Fauntleroy K, VanNieuwenhze MS, et al. Spheroplast-mediated carbapenem tolerance in Gram-negative pathogens. Antimicrob Agents Chemother. 2019;63(9):e00756-19. doi: 10.1128/AAC.00756-19 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Mickiewicz KM, Kawai Y, Drage L, Gomes MC, Davison F, Pickard R, et al. Possible role of L-form switching in recurrent urinary tract infection. Nat Commun. 2019;10(1):4379. doi: 10.1038/s41467-019-12359-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Claessen D, Errington J. Cell wall deficiency as a coping strategy for stress. Trends Microbiol. 2019;27(12):1025–33. doi: 10.1016/j.tim.2019.07.008 [DOI] [PubMed] [Google Scholar]
  • 10.Errington J. Cell wall-deficient, L-form bacteria in the 21st century: a personal perspective. Biochem Soc Trans. 2017;45(2):287–95. doi: 10.1042/BST20160435 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Shin J-H, Choe D, Ransegnola B, Hong H-R, Onyekwere I, Cross T, et al. A multifaceted cellular damage repair and prevention pathway promotes high-level tolerance to β-lactam antibiotics. EMBO Rep. 2021;22(2):e51790. doi: 10.15252/embr.202051790 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Dörr T, Alvarez L, Delgado F, Davis BM, Cava F, Waldor MK. A cell wall damage response mediated by a sensor kinase/response regulator pair enables beta-lactam tolerance. Proc Natl Acad Sci U S A. 2016;113(2):404–9. doi: 10.1073/pnas.1520333113 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Dörr T. Understanding tolerance to cell wall-active antibiotics. Ann N Y Acad Sci. 2021;1496(1):35–58. doi: 10.1111/nyas.14541 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Weaver AI, Murphy SG, Umans BD, Tallavajhala S, Onyekwere I, Wittels S, et al. Genetic determinants of penicillin tolerance in Vibrio cholerae. Antimicrob Agents Chemother. 2018;62(10):e01326-18. doi: 10.1128/AAC.01326-18 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Paczosa MK, Mecsas J. Klebsiella pneumoniae: going on the offense with a strong defense. Microbiol Mol Biol Rev. 2016;80(3):629–61. doi: 10.1128/MMBR.00078-15 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–55. doi: 10.1016/S0140-6736(21)02724-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Chen T-A, Chuang Y-T, Lin C-H. A decade-long review of the virulence, resistance, and epidemiological risks of Klebsiella pneumoniae in ICUs. Microorganisms. 2024;12(12):2548. doi: 10.3390/microorganisms12122548 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Cho H, Uehara T, Bernhardt TG. Beta-lactam antibiotics induce a lethal malfunctioning of the bacterial cell wall synthesis machinery. Cell. 2014;159(6):1300–11. doi: 10.1016/j.cell.2014.11.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Lobritz MA, Andrews IW, Braff D, Porter CBM, Gutierrez A, Furuta Y, et al. Increased energy demand from anabolic-catabolic processes drives β-lactam antibiotic lethality. Cell Chem Biol. 2022;29(2):276-286.e4. doi: 10.1016/j.chembiol.2021.12.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Held K, Gasper J, Morgan S, Siehnel R, Singh P, Manoil C. Determinants of extreme β-lactam tolerance in the Burkholderia pseudomallei complex. Antimicrob Agents Chemother. 2018;62(4):e00068-18. doi: 10.1128/AAC.00068-18 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Gefen O, Chekol B, Strahilevitz J, Balaban NQ. TDtest: easy detection of bacterial tolerance and persistence in clinical isolates by a modified disk-diffusion assay. Sci Rep. 2017;7:41284. doi: 10.1038/srep41284 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Ramage B, Erolin R, Held K, Gasper J, Weiss E, Brittnacher M, et al. Comprehensive arrayed transposon mutant library of Klebsiella pneumoniae outbreak strain KPNIH1. J Bacteriol. 2017;199(20):e00352-17. doi: 10.1128/JB.00352-17 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Ranjit DK, Jorgenson MA, Young KD. PBP1B glycosyltransferase and transpeptidase activities play different essential roles during the de novo regeneration of rod morphology in Escherichia coli. J Bacteriol. 2017;199(7):e00612-16. doi: 10.1128/JB.00612-16 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Weaver A, Taguchi A, Dörr T. Masters of misdirection: peptidoglycan glycosidases in bacterial growth. J Bacteriol. 2023;205(3):e0042822. doi: 10.1128/jb.00428-22 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Murtha AN, Kazi MI, Schargel RD, Cross T, Fihn C, Cattoir V, et al. High-level carbapenem tolerance requires antibiotic-induced outer membrane modifications. PLoS Pathog. 2022;18(2):e1010307. doi: 10.1371/journal.ppat.1010307 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Ranjit DK, Young KD. The Rcs stress response and accessory envelope proteins are required for de novo generation of cell shape in Escherichia coli. J Bacteriol. 2013;195(11):2452–62. doi: 10.1128/JB.00160-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Laubacher ME, Ades SE. The Rcs phosphorelay is a cell envelope stress response activated by peptidoglycan stress and contributes to intrinsic antibiotic resistance. J Bacteriol. 2008;190(6):2065–74. doi: 10.1128/JB.01740-07 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Rousseau CJ, Fraikin N, Zedek S, Van Melderen L. Are envelope stress responses essential for persistence to β-lactams in Escherichia coli? Antimicrob Agents Chemother. 2023;67(10):e0032923. doi: 10.1128/aac.00329-23 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Wall E, Majdalani N, Gottesman S. The complex Rcs regulatory cascade. Annu Rev Microbiol. 2018;72:111–39. doi: 10.1146/annurev-micro-090817-062640 [DOI] [PubMed] [Google Scholar]
  • 30.Harmange G, Hueros RAR, Schaff DL, Emert B, Saint-Antoine M, Kim LC, et al. Disrupting cellular memory to overcome drug resistance. Nat Commun. 2023;14(1):7130. doi: 10.1038/s41467-023-41811-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Shaffer SM, Dunagin MC, Torborg SR, Torre EA, Emert B, Krepler C, et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature. 2017;546(7658):431–5. doi: 10.1038/nature22794 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Singh A, Saint-Antoine M. Probing transient memory of cellular states using single-cell lineages. Front Microbiol. 2023;13:1050516. doi: 10.3389/fmicb.2022.1050516 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Hossain T, Singh A, Butzin NC. Escherichia coli cells are primed for survival before lethal antibiotic stress. Microbiol Spectr. 2023;11(5):e01219–23. doi: 10.1128/spectrum.01219-23 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Guha M, Singh A, Butzin NC. Priestia megaterium cells are primed for surviving lethal doses of antibiotics and chemical stress. Commun Biol. 2025;8(1):206. doi: 10.1038/s42003-025-07639-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Lee JJ, Swanson DH, Lee S-K, Dihardjo S, Lee GY, Gelle S, et al. Trehalose catalytic shift inherently enhances phenotypic heterogeneity and multidrug resistance in Mycobacterium tuberculosis. Nat Commun. 2025;16(1):6442. doi: 10.1038/s41467-025-61703-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Krishnamoorthy K, Lee M. Improved tests for the equality of normal coefficients of variation. Comput Stat. 2013;29(1–2):215–32. doi: 10.1007/s00180-013-0445-2 [DOI] [Google Scholar]
  • 37.Recacha E, Fox V, Díaz-Díaz S, García-Duque A, Docobo-Pérez F, Pascual Á, et al. Disbalancing envelope stress responses as a strategy for sensitization of Escherichia coli to antimicrobial agents. Front Microbiol. 2021;12:653479. doi: 10.3389/fmicb.2021.653479 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Rome K, Borde C, Taher R, Cayron J, Lesterlin C, Gueguen E, et al. The two-component system ZraPSR is a novel ESR that contributes to intrinsic antibiotic tolerance in Escherichia coli. J Mol Biol. 2018;430(24):4971–85. doi: 10.1016/j.jmb.2018.10.021 [DOI] [PubMed] [Google Scholar]
  • 39.Kenney LJ, Anand GS. EnvZ/OmpR two-component signaling: an archetype system that can function noncanonically. EcoSal Plus. 2020;9(1). doi: 10.1128/ecosalplus.ESP-0001-2019 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Groisman EA, Duprey A, Choi J. How the PhoP/PhoQ system controls virulence and Mg2+ homeostasis: lessons in signal transduction, pathogenesis, physiology, and evolution. Microbiol Mol Biol Rev. 2021;85(3):e0017620. doi: 10.1128/MMBR.00176-20 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Raivio TL. Everything old is new again: an update on current research on the Cpx envelope stress response. Biochim Biophys Acta. 2014;1843(8):1529–41. doi: 10.1016/j.bbamcr.2013.10.018 [DOI] [PubMed] [Google Scholar]
  • 42.Morè N, Martorana AM, Biboy J, Otten C, Winkle M, Serrano CKG, et al. Peptidoglycan remodeling enables Escherichia coli to survive severe outer membrane assembly defect. mBio. 2019;10(1):e02729-18. doi: 10.1128/mBio.02729-18 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Bernal-Cabas M, Ayala JA, Raivio TL. The Cpx envelope stress response modifies peptidoglycan cross-linking via the L,D-transpeptidase LdtD and the novel protein YgaU. J Bacteriol. 2015;197(3):603–14. doi: 10.1128/JB.02449-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Guest RL, Wang J, Wong JL, Raivio TL. A bacterial stress response regulates respiratory protein complexes to control envelope stress adaptation. J Bacteriol. 2017;199(20). doi: 10.1128/jb.00153-17 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Tsviklist V, Guest RL, Raivio TL. The Cpx stress response regulates turnover of respiratory chain proteins at the inner membrane of Escherichia coli. Front Microbiol. 2022;12:732288. doi: 10.3389/fmicb.2021.732288 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Carballès F, Bertrand C, Bouché JP, Cam K. Regulation of Escherichia coli cell division genes ftsA and ftsZ by the two-component system rcsC-rcsB. Mol Microbiol. 1999;34(3):442–50. doi: 10.1046/j.1365-2958.1999.01605.x [DOI] [PubMed] [Google Scholar]
  • 47.Thomson NM, Turner AK, Yasir M, Bastkowski S, Lott M, Webber MA, et al. A whole-genome assay identifies four principal gene functions that confer tolerance of meropenem stress upon Escherichia coli. Front Antibiot. 2022;1:957942. doi: 10.3389/frabi.2022.957942 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Islam N, Kazi MI, Kang KN, Biboy J, Gray J, Ahmed F, et al. Peptidoglycan recycling promotes outer membrane integrity and carbapenem tolerance in Acinetobacter baumannii. mBio. 2022;13(3):e0100122. doi: 10.1128/mbio.01001-22 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Crépin S, Ottosen EN, Peters K, Smith SN, Himpsl SD, Vollmer W, et al. The lytic transglycosylase MltB connects membrane homeostasis and in vivo fitness of Acinetobacter baumannii. Mol Microbiol. 2018;109(6):745–62. doi: 10.1111/mmi.14000 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Cavallari JF, Lamers RP, Scheurwater EM, Matos AL, Burrows LL. Changes to its peptidoglycan-remodeling enzyme repertoire modulate β-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2013;57(7):3078–84. doi: 10.1128/AAC.00268-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Lamers RP, Nguyen UT, Nguyen Y, Buensuceso RNC, Burrows LL. Loss of membrane-bound lytic transglycosylases increases outer membrane permeability and β-lactam sensitivity in Pseudomonas aeruginosa. Microbiologyopen. 2015;4(6):879–95. doi: 10.1002/mbo3.286 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Solaimanpour S, Sarmiento F, Mrázek J. Tn-seq explorer: a tool for analysis of high-throughput sequencing data of transposon mutant libraries. PLoS One. 2015;10(5):e0126070. doi: 10.1371/journal.pone.0126070 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Lazarus JE, Warr AR, Kuehl CJ, Giorgio RT, Davis BM, Waldor MK. A new suite of allelic-exchange vectors for the scarless modification of proteobacterial genomes. Appl Environ Microbiol. 2019;85(16):e00990-19. doi: 10.1128/AEM.00990-19 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Renee Fleeman

11 Dec 2025

PPATHOGENS-D-25-02804

Prevalence and mechanisms of high-level carbapenem antibiotic tolerance in clinical isolates of Klebsiella pneumoniae

PLOS Pathogens

Dear Dr. Dorr,

Thank you for submitting your manuscript to PLOS Pathogens. After careful consideration, we feel that it has merit but does not fully meet PLOS Pathogens's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Of particular note, the fluctuation test needs clarification to improve the understanding of this technique. Addressing the novelty of these findings, there are previous reports not mentioned in the manuscript that have implicated the factors identified here are important for cell envelope stress. Furthermore, as the current focus of tolerance is on growth rate, the results presented here showing that stress response mechanisms preserve non-growing cells should be explained in the context of growth rate to show how these findings change our current understanding of tolerance.

Please submit your revised manuscript by February 10th 2026. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plospathogens@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/ppathogens/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

* A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. This file does not need to include responses to any formatting updates and technical items listed in the 'Journal Requirements' section below.

* A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

* An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

Renee M. Fleeman

Guest Editor

PLOS Pathogens

Matthew Wolfgang

Section Editor

PLOS Pathogens

Sumita Bhaduri-McIntosh

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0003-2946-9497

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

Journal Requirements:

If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

1) Please ensure that the CRediT author contributions listed for every co-author are completed accurately and in full.

At this stage, the following Authors/Authors require contributions: Trevor Cross, Facundo Torres, Nadia Nikulin, Abigail P McGee, Leena Jalees, Rhea Balakrishnan, Tolani Aliyu, Lars Westblade, Abhyudai Singh, and Tobias Dörr. Please ensure that the full contributions of each author are acknowledged in the "Add/Edit/Remove Authors" section of our submission form.

The list of CRediT author contributions may be found here: https://journals.plos.org/plospathogens/s/authorship#loc-author-contributions

2) We ask that a manuscript source file is provided at Revision. Please upload your manuscript file as a .doc, .docx, .rtf or .tex. If you are providing a .tex file, please upload it under the item type u2018LaTeX Source Fileu2019 and leave your .pdf version as the item type u2018Manuscriptu2019.

3) Please provide an Author Summary. This should appear in your manuscript between the Abstract (if applicable) and the Introduction, and should be 150-200 words long. The aim should be to make your findings accessible to a wide audience that includes both scientists and non-scientists. Sample summaries can be found on our website under Submission Guidelines:

https://journals.plos.org/plospathogens/s/submission-guidelines#loc-parts-of-a-submission

4) Please upload all main figures as separate Figure files in .tif or .eps format. For more information about how to convert and format your figure files please see our guidelines:

https://journals.plos.org/plospathogens/s/figures

5) We notice that your supplementary Figures are included in the manuscript file. Please remove them and upload them with the file type 'Supporting Information'. Please ensure that each Supporting Information file has a legend listed in the manuscript after the references list.

6) Some material included in your submission may be copyrighted. According to PLOSu2019s copyright policy, authors who use figures or other material (e.g., graphics, clipart, maps) from another author or copyright holder must demonstrate or obtain permission to publish this material under the Creative Commons Attribution 4.0 International (CC BY 4.0) License used by PLOS journals. Please closely review the details of PLOSu2019s copyright requirements here: PLOS Licenses and Copyright. If you need to request permissions from a copyright holder, you may use PLOS's Copyright Content Permission form.

Please respond directly to this email and provide any known details concerning your material's license terms and permissions required for reuse, even if you have not yet obtained copyright permissions or are unsure of your material's copyright compatibility. Once you have responded and addressed all other outstanding technical requirements, you may resubmit your manuscript within Editorial Manager.

Potential Copyright Issues:

i) Figure 8. Please confirm whether you drew the images / clip-art within the figure panels by hand. If you did not draw the images, please provide (a) a link to the source of the images or icons and their license / terms of use; or (b) written permission from the copyright holder to publish the images or icons under our CC BY 4.0 license. Alternatively, you may replace the images with open source alternatives. See these open source resources you may use to replace images / clip-art:

- https://commons.wikimedia.org

- https://openclipart.org/.

7) Please amend your detailed Financial Disclosure statement. This is published with the article. It must therefore be completed in full sentences and contain the exact wording you wish to be published.

1) State the initials, alongside each funding source, of each author to receive each grant. For example: "This work was supported by the National Institutes of Health (####### to AM; ###### to CJ) and the National Science Foundation (###### to AM)."

2) State what role the funders took in the study. If the funders had no role in your study, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

3) If any authors received a salary from any of your funders, please state which authors and which funders..

If you did not receive any funding for this study, please simply state: u201cThe authors received no specific funding for this work.u201d

8) Please send a completed 'Competing Interests' statement, including any COIs declared by your co-authors. If you have no competing interests to declare, please state "The authors have declared that no competing interests exist". Otherwise please declare all competing interests beginning with the statement "I have read the journal's policy and the authors of this manuscript have the following competing interests"

Reviewers' Comments:

Reviewer's Responses to Questions

Part I - Summary

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer #1: Cross et al. examines the prevalence of carbapenem tolerance in a large panel of Enterobacterales bloodstream isolates. They show that Klebsiella pneumoniae strains exhibited the highest overall tolerance to the last line antibiotic meropenem. The authors employed an existing transposon library and elegant microscopy to uncover the mechanism of meropenem tolerance in K. pneumoniae. Their study links tolerance to envelope-stress systems (Rcs, PhoPQ, Cpx, OmpR/EnvZ) and identifies lytic transglycosylases as anti-tolerance factors, connecting survival to spheroplast formation and recovery. The mechanistic studies were well controlled with appropriate complemented strains in the supplementary materials.

A major strength is the high-throughput tolerance screen that still works despite MIC and growth-rate differences typically observed in panels of clinical isolates. Using a single fixed meropenem concentration (appropriate for time-dependent β-lactam killing) and quenching with a carbapenemase to avoid wash steps are innovative design choices. The screen’s rankings translated well to quantitative time-kill assays and will be of particular interest to the antibiotic tolerance community.

The manuscript would benefit from some additional discussion on if spheroplasts could contribute to carbapenem treatment failure in patients. Overall, this is an important study that shifts the focus beyond antibiotic resistance and highlights the need for understanding and targeting tolerance mechanisms.

Reviewer #2: In their manuscript entitled “Prevalence and mechanisms of high-level carbapenem antibiotic tolerance in clinical isolates of Klebsiella pneumoniae”, the authors characterize meropenem tolerance in clinical isolates in a range of species. Finding K. pneumoniae to be particularly tolerant to meropenem, subsequent work was focused on characterizing the genetic requirements for meropenem tolerance in K. pneumoniae. The work presented here provides molecular insight into the signaling pathways promoting tolerance in the presence of meropenem and potentially other beta-lactam antibiotics. I really appreciated the medium throughput assay for tolerance phenotypes in their collection of clinical K. pneumoniae isolates. The use of the carbapenemase to scavenge meropenem for the plating assay was very clever.

Altogether, the results suggest a collective and potentially sequentially activated stress response that is protective to K. pneumoniae grown in the presence of meropenem. At the same time, why and how this response leads to a halt in cell growth remains an open question, but an important one given the established connection between tolerance and slow growth at the population and single cell level. Is it possible that the cell envelope stress response preserves viability just long enough for cells to enter a slow growing, tolerant state? Finally, the rationale for some of the experiments, particularly the unusual use of the fluctuation test, is unclear and there are additional instances where more precise use of language and/or more clarity would be welcome.

Reviewer #3: The study by Cross et al. explores the prevalence and mechanisms behind carbapenem tolerance among clinical isolates of Klebsiella pneumoniae. Through screening of 271 bloodstream isolates Cross et all. identify higher prevalence of tolerance in K. pneumoniae isolates than in E. coli. A hyper-tolerant strain, TS1, survived nearly all meropenem exposure by forming cell wall‑deficient spheroplasts that recovered once the drug was removed. Using transposon sequencing, the authors identified cell envelope stress response systems (PhoPQ, Cpx, Rcs, OmpR/EnvZ) as essential for spheroplast stability and recovery, while the lytic transglycosylase MltB disrupted tolerance.

The area under scrutiny is clinically relevant and timely. Our understanding of the breadth of tolerance in clinically relevant context is important and the possibility that targeting stress response pathways or enzymes like MltB could aid eradication of tolerant infections is of broad interest.

**********

Part II – Major Issues: Key Experiments Required for Acceptance

Please use this section to detail the key new experiments or modifications of existing experiments that should be absolutely required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a "Major Revision" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend "Reject".

Reviewer #1: NA

Reviewer #2: 1. The fluctuation test is an unusual way to examine what appear to be non-heritable phenomena. Is the idea to look at variation in single cell responses? Overall, this section would be improved by revising for clarity as well as improving the presentation of the data. Specifically:

a. While there are details of the experimental method in the results sections, I didn’t see a methods section for this experiment. That should be included for reproducibility. How many wells were examined for each strain? Based on the graphs provided it looks like there are more replicates of the Δ4 in the 1 cell condition than WT.

b. Is OD600 a truly robust or meaningful readout for spheroplast populations when the Δ4 population doesn’t appear to readily generate spheroplasts (Fig 5C)?

c. There’s only one value on the Y-axis. Perhaps a supplemental figure could be included that show more clearly the areas between the meropenem added and when CV was calculated?

2. The authors need to address how their findings fit into the current understanding of factors underlying antibiotic tolerance, particularly with regard to growth rate. E.g. is expression of the stress response systems protective immediately following challenge with meropenem?

Reviewer #3: Tolerance assay:

It appears that only a single replicate is shown. Given that the rest of the manuscript relies on these observations, at least 3 biological replicates should be carried out and presented.

Fig 2B and 4C:

Please provide the number of cell frames imaged and information on biological replicates. Additional panels from the sample showing the prevalence of the observed phenotypes should be included in supplementary.

Statistical analysis for several figures is missing and should be included:

- Ln 120: statistical significance of the correlation is mentioned but not shown. I agree with the conclusion that biological significance is not present however given the analysis is mentioned, it should be included in the legend along with its results.

- Fig 6B: statistical analysis is missing, please correct.

- Fig 5: Please add details on replicates and statistics.

**********

Part III – Minor Issues: Editorial and Data Presentation Modifications

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer #1: 1. Presumably spheroplasts are very susceptible to other stresses. Can the authors comment on if these spheroplast could be a mechanism of tolerance that occurs during treatment of bloodstream infections.

2. Related: Are the tolerant K. pneumoniae spheroplasts still capsulated? If so, could the capsule provide protection from killing by whole blood?

3. Line 413-415: Interpretation of the fluctuation test results should be expanded to improve clarity. Does this result suggest that meropenem tolerant cells (spheroplasts) are pre-existing in this population before the addition of the drug? If so, could similar experiments be performed in more physiologically relevant conditions (serum or blood) to see if the trend holds up?

Reviewer #2: Major Comments:

1. The authors present TN-seq and mutant data to support a requirement for cell envelope stress response systems in meropenem tolerance. This work was performed in the TS1 strain, which exhibited higher tolerance to meropenem than E. coli MG1655 or another K. pneumoniae strain, KPNIH1. These cell envelope stress systems are broadly conserved in Gram-negative bacteria and not unique to TS1. How do these systems contribute to the underlying base-line differences in tolerance between organisms/strains? Do the author’s have any insights into why TS1 is more tolerant than other strains?

2. Is Meropenem special? The title suggests this phenomenon holds for all carbapenems but I don’t think this has been tested. If Meropenem is special or is the only drug tested the title should be revised to reflect this.

3. Do the authors have any thoughts as to why overexpression of rcsB seems to impair survivability in a WT background? (Fig 6 B).

4. The author’s find that loss of MltB and SltY, both of which should lead to accumulation of glycan strands, increase tolerance. I believe this is not unexpected result based on Cho et al 2014, who found that defects in the E. coli soluble lytic transglycosylase, SltA are protective in the presence of mecillinam, in accordance with their futile cycle model for beta-lactam killing in E. coli. This same paper indicates that a defect in mltB “imparts a fitness advantage in the presence of meropenem” which I believe similar to this study’s finding in K. pneumoniae if one assumes tolerance and resistance share overlapping mechanisms. Regardless, the relationship between this finding and those of Cho et al should be addressed in the results and/or discussion.

Minor Comments

1. Line 25: “novel” might not be the correct word. Most of these genes have been previously implicated in the response to cell envelope stress. Could just say identified cell envelope stress related factors as important for tolerance.

2. Line 40. Clarify that tolerance means “survive but do not grow”

Reviewer #3: Data/Analysis:

- Fig 3B: was a cut-off implemented for prioritizing genes for further validation?

- Ln 230-232: Given the validation hits seem to have been selected by picking hits that have exhibited low insertion rate after exposure – how were the two ‘survival supporting’ hits picked up? Surely those would have shown a complete opposite phenotype on the insertion rates? … I could find neither MltB or OsmB in table S4 so this cannot be extrapolated from there.

- Fig 4B: TS1 appears to afford almost the same survival as KPNIH1 mltB mutant - is the TS1 deficient or lacking the expression the mltB or is this phenotype arising from another variation?

- It is unclear why the stress responses are studied in TS1 but the prior section is done in KPNIH1, especially since the KPNIH library seems to exist – why were different mutants created in the TS1 background and the KPNIH library not exploited?

Figure/Table comments:

- Supplementary Table 1: Please clarify what this table is showing. Given Ln 143, this table appears to link to tolerance phenotypes, however its first mention at Ln65 which discusses resistance makes the data presented in this table difficult to place.

- Ln 163 and Table S2: MIC values are mismatched for TS1, please correct.

- Fig 3C: The y-axis is a little misleading. Are those fractions of survival of CFU per mL?

- Ln 400 and Fig 7: legend do not match. The figure implies that CV calculations were done at the blue dotted line timepoint while the main text suggests this was carried out at the red line timepoint. Please clarify.

Textual comments:

- Ln 64–65: Please reference for sentence starting “In some bacteria…”

- Ln 146: Please remove the stray “.” after “species”.

- Ln 244: Please define LTG.

- Ln 309: Please remove the aberrant “mutant” word.

- Ln 318: Please define CESR.

- Fig S4: appears in the text prior to FigS3, please correct the order.

- Ln 318-319 : ‘CESR single deletion mutants formed spheroplasts, albeit at much lower numbers compared to WT.’ is followed by a statement saying that 2/4 are exceptions. I would consider removing the above highlighted sentence and covering each deletion separately, especially given that half of the 4 mentioned are actually not what is described, essentially implying there is no single unique trend (beyond the overall tolerance effect)

- Ln 319-325: The structure of this paragraph is a little disjointed and hard to follow. I would suggest discussing all points on the rcs system first and then moving all the ompR/envZ.

- Ln 385: please remove ‘both’ when discussing 3 species.

- Throughout the manuscript hyphenation is often missing between ‘number(-)fold’.

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

Figure resubmission:

While revising your submission, we strongly recommend that you use PLOS’s NAAS tool (https://ngplosjournals.pagemajik.ai/artanalysis) to test your figure files. NAAS can convert your figure files to the TIFF file type and meet basic requirements (such as print size, resolution), or provide you with a report on issues that do not meet our requirements and that NAAS cannot fix.

After uploading your figures to PLOS’s NAAS tool - https://ngplosjournals.pagemajik.ai/artanalysis, NAAS will process the files provided and display the results in the "Uploaded Files" section of the page as the processing is complete. If the uploaded figures meet our requirements (or NAAS is able to fix the files to meet our requirements), the figure will be marked as "fixed" above. If NAAS is unable to fix the files, a red "failed" label will appear above. When NAAS has confirmed that the figure files meet our requirements, please download the file via the download option, and include these NAAS processed figure files when submitting your revised manuscript.

Reproducibility:

To enhance the reproducibility of your results, we recommend that authors of applicable studies deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Decision Letter 1

Renee Fleeman

12 Jan 2026

PPATHOGENS-D-25-02804R1

Prevalence and mechanisms of high-level carbapenem antibiotic tolerance in clinical isolates of Klebsiella pneumoniae

PLOS Pathogens

Dear Dr. Dörr,

Thank you for submitting your manuscript to PLOS Pathogens. While the reviewers agree the current version of the manuscript is much improved, there are minor concerns to address. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Mar 13 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plospathogens@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/ppathogens/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

* A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. This file does not need to include responses to any formatting updates and technical items listed in the 'Journal Requirements' section below.

* A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

* An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

Renee M. Fleeman

Guest Editor

PLOS Pathogens

Matthew Wolfgang

Section Editor

PLOS Pathogens

Sumita Bhaduri-McIntosh

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0003-2946-9497

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

Journal Requirements:

If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Reviewers' Comments:

Reviewer's Responses to Questions

Part I - Summary

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer #1: All of my comments have been addressed

Reviewer #2: The authors have done an excellent job responding to reviewer comments.

Reviewer #3: I would like to thank the authors for their thoughtful revisions to the manuscript. Your updated explanations across the sections help place the findings in a broader context while the strengthened additional method details and improvements to the organization and legends, makes the study clearer and easier to follow. Overall, the revisions have significantly improved the manuscript, and I appreciate the care you put into addressing the feedback. I have no further concerns.

**********

Part II – Major Issues: Key Experiments Required for Acceptance

Please use this section to detail the key new experiments or modifications of existing experiments that should be absolutely required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a "Major Revision" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend "Reject".

Reviewer #1: All of my comments have been addressed

Reviewer #2: (No Response)

Reviewer #3: n/a

**********

Part III – Minor Issues: Editorial and Data Presentation Modifications

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer #1: All of my comments have been addressed

Reviewer #2: While I understand that meropenem is a representative carbapenem, the data do not support the idea that K. pneumoniae will respond to other carbapenems in the same way. To avoid confusion, I respectfully request title be revised to either specify that drug tested was meropenem or at least to indicate that only one carbapenem was tested. E.g. "Prevalence and mechanisms of high-level antibiotic tolerance to a representative carbapenem in clinical isolates of Klebsiella pneumoniae"

Reviewer #3: There is a lack of italicization on ln 40 for Klebsiella pneumoniae

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

Figure resubmission:

While revising your submission, we strongly recommend that you use PLOS’s NAAS tool (https://ngplosjournals.pagemajik.ai/artanalysis) to test your figure files. NAAS can convert your figure files to the TIFF file type and meet basic requirements (such as print size, resolution), or provide you with a report on issues that do not meet our requirements and that NAAS cannot fix.

After uploading your figures to PLOS’s NAAS tool - https://ngplosjournals.pagemajik.ai/artanalysis, NAAS will process the files provided and display the results in the "Uploaded Files" section of the page as the processing is complete. If the uploaded figures meet our requirements (or NAAS is able to fix the files to meet our requirements), the figure will be marked as "fixed" above. If NAAS is unable to fix the files, a red "failed" label will appear above. When NAAS has confirmed that the figure files meet our requirements, please download the file via the download option, and include these NAAS processed figure files when submitting your revised manuscript.

Reproducibility:

To enhance the reproducibility of your results, we recommend that authors of applicable studies deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Decision Letter 2

Renee Fleeman

20 Jan 2026

Dear Dr. Dörr,

We are pleased to inform you that your manuscript 'Prevalence and mechanisms of high-level carbapenem antibiotic tolerance in clinical isolates of Klebsiella pneumoniae' has been provisionally accepted for publication in PLOS Pathogens.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Renee M. Fleeman

Guest Editor

PLOS Pathogens

Matthew Wolfgang

Section Editor

PLOS Pathogens

Sumita Bhaduri-McIntosh

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0003-2946-9497

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

***********************************************************

Reviewer Comments (if any, and for reference):

Acceptance letter

Renee Fleeman

Dear Dr. Dörr,

We are delighted to inform you that your manuscript, "Prevalence and mechanisms of high-level carbapenem antibiotic tolerance in clinical isolates of Klebsiella pneumoniae," has been formally accepted for publication in PLOS Pathogens.

We have now passed your article onto the PLOS Production Department who will complete the rest of the pre-publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Pearls, Reviews, Opinions, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript, if you opted to have an early version of your article, will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

For Research Articles, you will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Sumita Bhaduri-McIntosh

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0003-2946-9497

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Text

    Fig A. Tolerance screen validation with benchmark isolates. Strains were exposed to meropenem (10 µg/mL) as described in methods. At the indicated time-points, 10 µL of the cell suspension was spotted on BHI agar and supplemented with KPC, followed by 24 hours of incubation at 37 ˚C. Fig B. Complementation of the ∆mltB phenotype. The indicated strains were grown overnight in BHI, then diluted 10-fold into fresh BHI containing meropenem (10 µg/mL) and 40 ng/mL anhydrotetracycline. Viability was determined by serial dilution and spot-plating after 24 hours of incubation. Shown are raw data points for 5 biological replicates for each strain. Statistical significance was determined by Mann Whitney test (*p < 0.05). Fig C. Tolerance phenotypes of CESR mutants. Time-dependent killing experiments (10 µg/mL meropenem) were conducted in BHI medium. Statistical analysis (Kruskal-Wallace test, p < 0.001) revealed statistically significant differences in viability (12 hour time point) for all mutants vs. WT; ∆4 vs. any triple mutant was not statistically significant. Fig D. Complementation of the ∆CESR phenotypes. The indicated strains were grown overnight in BHI, then diluted 10-fold into fresh BHI containing meropenem (10 µg/mL) and 40 ng/mL anhydrotetracycline and incubated for 24 hours. Viability was determined by serial dilution and spot-plating. Shown are boxplot and raw data points for at least 5 biological replicates for each strain. Fig E. Meropenem induces the Rcs phosphorelay. A) The PrprA-lacZ reporter strain was spread on plates containing the chromogenic LacZ substrate x-gal. A filter disk was placed in the middle containing either meropenem or kanamycin. Note blue halo around the meropenem disk, in the sub-MIC area beyond the zone of inhibition. B) RcsB was overexpressed from an arabinose-inducible promoter in the PrprA-lacZ background, followed by plating on LB with X-gal.

    (DOCX)

    ppat.1013919.s001.docx (944.3KB, docx)
    S1 Table. Summary of Bloodstream Isolate Panel Distribution in tolerance categories.

    Shown are the number of isolates for each species in each tolerance category.

    (XLSX)

    ppat.1013919.s002.xlsx (32KB, xlsx)
    S2 Table. MICs of the strains used in this study.

    (XLSX)

    ppat.1013919.s003.xlsx (9.2KB, xlsx)
    S3 Table. Bloodstream isolate panel.

    (XLSX)

    ppat.1013919.s004.xlsx (9.5KB, xlsx)
    S4 Table. TnSeq insertion frequencies.

    (XLSX)

    ppat.1013919.s005.xlsx (1.3MB, xlsx)
    S5 Table. Strains used in this study.

    (XLSX)

    ppat.1013919.s006.xlsx (14KB, xlsx)
    S6 Table. Oligos used in this study.

    (XLSX)

    ppat.1013919.s007.xlsx (14.1KB, xlsx)
    Attachment

    Submitted filename: Reviewer_Response_KlebTol2.docx

    ppat.1013919.s008.docx (28KB, docx)
    Attachment

    Submitted filename: Reviewer_response_final.docx

    ppat.1013919.s009.docx (13.8KB, docx)

    Data Availability Statement

    All relevant data are in the manuscript and its Supporting information files.


    Articles from PLOS Pathogens are provided here courtesy of PLOS

    RESOURCES